ClinicalTrials.gg
Not yet recruitingNCT07075003Updated Jul 20, 2025

NOL-Guided vs Conventional Intraoperative Opioid Infusion on Outcomes in Geriatric Patients

An observational study in Pain, Opioid Use and Geriatric Anesthesia, sponsored by Saglik Bilimleri Universitesi. Not yet recruiting. Open to participants aged 65 Years to 90 Years. Per ClinicalTrials.gov, last updated 2025-07-20.

Sponsored by Saglik Bilimleri Universitesi · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Sep 2025, 1 year 2 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
80
Ages
65 Years to 90 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 33 studies in Pain by Saglik Bilimleri Universitesi — 6 open to participants now, 8 under way, none of them phase 3. Pain · Saglik Bilimleri Universitesi.

Started
2025
with 6 others
Observational
Only one
of the 33
Registered
25th of 33
by date

Among the 33 studies in Pain by Saglik Bilimleri Universitesi, this one is one of 7 that started in 2025, is the only observational one, and was the 25th registered.

Pain

10,076 studies on the registry are indexed under Pain; 1,648 are open to participants now.

Browse Pain studies →

Open to participants now

6 of the 33 studies in Pain by Saglik Bilimleri Universitesi are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Where they have run

Who these studies take

Of the 930 Pain studies recruiting now, 384 (41%) set no upper age limit and 434 (47%) stop at 75 or younger; 146 take children under 18; 220 take healthy volunteers.

This study: 65 Years to 90 Years · all sexes.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 33 studies in Pain by Saglik Bilimleri Universitesi, or all of them as a file.
02

Study summary

The aim of this study is to compare the effects of conventional methods and goal-directed therapy guided by pain monitoring on total remifentanil dosage, wake-up time, and complications in geriatric patients undergoing lumbar stabilization surgery.

Read the detailed description

With the aging population, the number of geriatric patients undergoing surgery is increasing daily. One of the anesthesiologists' main responsibilities is to prevent intraoperative pain and related complications. Opioids have been known for thousands of years as valuable tools for pain management and remain the cornerstone of perioperative analgesia today (1). Remifentanil is currently the most commonly used opioid during the intraoperative period due to its potent analgesic properties, short duration of action, and metabolism by plasma enzymes. While it may improve hemodynamic stability, remifentanil can also cause hypotension and bradycardia. Prolonged remifentanil use may lead to hyperalgesia, increasing the need for postoperative opioid analgesics and consequently leading to opioid-related side effects. In elderly patients, changes in body composition, drug sensitivity, and hepatic/renal metabolism require more cautious opioid administration.

Optimizing remifentanil infusion dosing during surgery may reduce total opioid consumption and thus decrease side effects such as wake-up time, postoperative pain, and nausea.

In conventional use, remifentanil is administered as a continuous infusion, and dosage adjustments are made based on heart rate and blood pressure changes to estimate pain levels. However, with goal-directed therapy guided by pain monitoring, more effective analgesia can be achieved. These applications are selected based on the clinician's experience and preferences. While some publications report that total remifentanil use decreases in patients with dose adjustments guided by pain monitoring, evidence is lacking regarding which method is superior in terms of patient outcomes in elderly populations.The aim of this study is to compare the effects of conventional methods and goal-directed therapy guided by pain monitoring on total remifentanil dosage, wake-up time, and complications in geriatric patients undergoing lumbar stabilization surgery.

After obtaining informed consent, a total of 80 geriatric patients undergoing lumbar stabilization surgery will be included. Once on the operating table, all patients will receive standard monitoring including peripheral oxygen saturation, non-invasive blood pressure, ECG, and anesthesia depth. All patients will receive intravenous 2-2.5 mg/kg propofol under Sedline guidance, and remifentanil via target-controlled infusion at an effect-site concentration of 4 ng/ml. After anesthesia depth falls below 50, 0.6 mg/kg rocuronium will be administered. Maintenance anesthesia will be with 1-2% sevoflurane in 40/60% oxygen/air mixture at 2 L flow. The method of remifentanil administration will be determined by the attending anesthesiologist.

Demographic data (age, height, weight, gender, comorbidities, ASA score) will be recorded. Hemodynamic parameters (blood pressure, heart rate, oxygen saturation, end-tidal CO₂), remifentanil dosage, and NOL levels (for Group 2) will be recorded every 15 minutes during the surgery. At the end of surgery, the following will be documented:

Total remifentanil dosage Blood loss and transfusion volume Number of hypotensive events (MAP \<55) Wake-up time Total surgical time NRS (Numerical Rating Scale) pain scores Nausea-vomiting scores

In the post-anesthesia care unit (PACU), pain and nausea-vomiting scores will be evaluated at the 10th, 20th, and 30th minutes, along with duration of PACU stay. During ward follow-up, pain scores, nausea-vomiting scores, administered medications, and length of postoperative hospital stay will be recorded at 1, 3, 6, and 24 hours.

Nausea-vomiting will be assessed using a 4-point scale:

0: none

  1. nausea without vomiting
  2. nausea with vomiting
  3. vomiting more than twice

Pain will be assessed using the NRS scale.

03

Conditions studied

  • Pain
  • Opioid Use
  • Geriatric Anesthesia

Browse trials for

04

Who can participate

Ages eligible
65 Years to 90 Years
Sexes eligible
All
Sampling method
Probability sample

Study population

A total of 80 geriatric patients undergoing lumbar stabilization surgery

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients undergoing lumbar stabilization surgery

Exclusion criteria

Exclusion Criteria:

  • Chronic opioid use
  • Severe congestive heart failıure
  • Severe arrhythmia
  • Uncontrolled hypertension
05

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
80 participants (estimated)
Patient registry
No

Groups and cohorts

  • Conservative

    Our clinic's standard anesthesia induction and maintenance method will be applied to all patients. Patients will receive standard monitoring including peripheral oxygen saturation, non-invasive blood pressure, ECG, and anesthesia depth. All patients will receive intravenous 2-2.5 mg/kg propofol under Sedline guidance, and remifentanil via target-controlled infusion at an effect-site concentration of 4 ng/ml. After anesthesia depth falls below 50, 0.6 mg/kg rocuronium will be administered. Maintenance anesthesia will be with 1-2% sevoflurane in 40/60% oxygen/air mixture at 2 L flow.Remifentanil is administered as a continuous infusion in conservative approach;dosage adjustments are made based on heart rate and blood pressure changes to estimate pain levels.

  • Nociceptive level

    Our clinic's standard anesthesia induction and maintenance method will be applied to all patients. Patients will receive standard monitoring including peripheral oxygen saturation, non-invasive blood pressure, ECG, and anesthesia depth. All patients will receive intravenous 2-2.5 mg/kg propofol under Sedline guidance, and remifentanil via target-controlled infusion at an effect-site concentration of 4 ng/ml. After anesthesia depth falls below 50, 0.6 mg/kg rocuronium will be administered. Maintenance anesthesia will be with 1-2% sevoflurane in 40/60% oxygen/air mixture at 2 L flow.Remifentanil is administered as a continuous infusion by using Nociceptive level guidance

    Device: nociceptive level

Interventions

  • Devicenociceptive level

    remifentanil infusion dose adjustment according to the changes of nociceptive level

06

What researchers measure

Primary outcomes

  1. Total dose

    Total dose of remifentanil used in operation

    Time frame: operation duration

Secondary outcomes

  1. postoperative pain

    pain evaluation during postoperative 24 hour, 11 point Numeric Rating Scale (NRS) will be used to measure pain level (0-10) 0: No pain, 10: Worst possible pain

    Time frame: postoperative 10th, 20th, and 30th minutes, 1, 3, 6, and 24 hours

  2. nausea and vomiting

    postoperative nausea and vomiting Nausea-vomiting will be assessed using a 4-point scale: 0: none 1. nausea without vomiting 2. nausea with vomiting 3. vomiting more than twice

    Time frame: postoperative 10th, 20th, and 30th minutes, 1, 3, 6, and 24 hours

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Gazelka HM, Leal JC, Lapid MI, Rummans TA. Opioids in Older Adults: Indications, Prescribing, Complications, and Alternative Therapies for Primary Care. Mayo Clin Proc. 2020 Apr;95(4):793-800. doi: 10.1016/j.mayocp.2020.02.002. PubMed 32247352 ↗
  • Hwang W, Lee J, Park J, Joo J. Dexmedetomidine versus remifentanil in postoperative pain control after spinal surgery: a randomized controlled study. BMC Anesthesiol. 2015 Feb 24;15:21. doi: 10.1186/s12871-015-0004-1. eCollection 2015. PubMed 25750586 ↗
  • Mercadante S. Influence of aging on opioid dosing for perioperative pain management: a focus on pharmacokinetics. J Anesth Analg Crit Care. 2024 Aug 1;4(1):51. doi: 10.1186/s44158-024-00182-2. PubMed 39085914 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jul 2025; primary completion for Sep 2025, 2 months later.

Of 505 non-industry observational studies under Pain, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 42. This study's planned 2 months is below that.

Counting every sponsor, half of 520 studies reached it within 18 months; a quarter within 8 and three quarters within 41.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 1, 2025
First posted
Jul 20, 2025
StartEst.
Jul 2025
Primary completionEst.
Sep 2025
CompletionEst.
Oct 2025
Last update
Jul 20, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 20, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07075003
Responsible party
Süheyla Abitağaoğlu (Associate Professor, MD, Saglik Bilimleri Universitesi) — Principal investigator
First posted
Jul 20, 2025
Start date
Jul 2025 (estimated)
Primary completion
Sep 2025 (estimated)
Completion
Oct 2025 (estimated)
Last update
Jul 20, 2025

Study contacts

Süheyla Abitağaoğlu
Contact
suheylaatay81@gmail.com
05325267656
Süheyla Abitağaoğlu
principal investigator · UNIVERSİTY OF HEALTH SCIENCES

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion